US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Atsena Therapeutics

News headline image
Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives Orphan Designation from the European Medicines Agency (EMA) for ATSN-101 and ATSN-201
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Presents Positive Clinical Data from Its XLRS and LCA1 Gene Therapy Programs at ARVO 2026
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Upcoming Presentations at Scientific and Medical Meetings
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part C Cohort
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present at May Scientific Conferences
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at The Macula Society’s 48th Annual Meeting
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Dosing Completed in Part A of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at the American Academy of Ophthalmology 2024 Annual Meeting
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire